Replies to post #1670 on Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

ABBV 3Q18 results—HCV sales=$862M (vs ABBV’s $850M guidance):

https://investors.abbvie.com/static-files/184e032f-41e4-4324-a0c9-6683bbef9781

ABBV’s 3Q18 HCV sales were $444M US (+5% QoQ) and $418M ex-US (-24% QoQ). (The $418 ex-US total includes $23M of Viekira sales.)